Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
A treatment study is being conducted by the University of Rochester Cancer Center (URCC) in
which patients with non-small cell lung cancer will be treated with radiation therapy and a
drug called paclitaxel. Paclitaxel is a natural product with anticancer properties. The first
purpose of this study is to determine the dose of paclitaxel which, when given in combination
with radiation therapy, will provide the greatest effect have the least side effects. To
determine this, patients will be put on the study in groups of 3. The dose for each
additional group will be higher than the previous dose until the maximum tolerated dose is
reached. The second purpose is to determine if radiation therapy with paclitaxel is more
effective in treating lung cancer than radiation therapy alone.